comparemela.com

Latest Breaking News On - Cepharanthine - Page 1 : comparemela.com

Patient, Physician Viewpoints Differ Regarding AA Severity, Treatment Satisfaction

A Japanese study of alopecia areata (AA) found misalignment between patient and doctor perceptions of severity, limiting treatment options, and leading to dissatisfaction and unmet needs.

Japanese dermatological associationImage creditHospital anxietyDepression scaleAlopecia areataPatient physician severityTreatment satisfactionScalp hair lossSkindex 16Hads scaleIntralesional injectionsCarpronium chlorideSquaric acid dibutyl esterQuality of lifeOral or intravenous corticosteroidsPsychological comorbidities

PharmaDrug Inc : PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer

Toronto, Ontario (Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development

United statesWangy cepharanthineDaniel cohenPharmadrug incDrug administrationNational cancer institute surveillanceNewsfile corpAustralia therapeutic goods administrationAustralia researchGenvion corporationAmerican cancer societyTherapeutic goods administrationEnteric coated oral cepharanthineValidated studies reveal potentialEnabling esophageal cancerSairiyo therapeutics

PharmaDrug Inc : PharmaDrug Successfully Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001, Its Patented, Orally Available Version of Cepharanthine for Oncology and Infectious Disease

Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substanceClinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled

United statesSouth africaJapan generalSouth africanWangy cepharanthineDaniel cohenBaillyc cepharanthineNewsfile corpDevelopment paths for oncologyPharmadrug incDrug administrationGenvion corporationDevelopment pathsInfectious disease createEnteric coated oral cepharanthineValidated studies reveal potential

PharmaDrug Inc : PharmaDrug Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study

Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel

United statesWangy cepharanthineDaniel cohenBaillyc cepharanthineSchedulei european unionPharmadrug incNational cancer institute surveillanceNewsfile corpEuropean unionEndresults programAmerican cancer societyEnteric coated oral cepharanthineDrug designationPharmadrug production gmbhSairiyo therapeuticsSuper smart

Pharmadrug Inc : Pharmadrug Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of Its Cepharanthine for Treatment of Mild to Moderate COVID-19 Infection

Established alignment with FDA on the path forward for the development of PD-001, a patented enteric-coated formulation of cepharanthine, towards clinical studies for mild-moderate COVID-19 infectionMeeting

United statesSouth africaJapan generalBaden wübergSouth africanDaniel cohenVan slykeBaillyc cepharanthineNewsfile corpSchedulei european unionPharmadrug incEuropean unionDrug administrationBreakthrough designationManufacturing controlChief scientific officer

vimarsana © 2020. All Rights Reserved.